Japan's Astellas bids $3.5 billion for OSI Pharma (Reuters via Yahoo! News)

Japan's Astellas Pharma Inc (4503.T) launched a $3.5 billion hostile bid for OSI Pharmaceuticals to gain access to the U.S. company's Tarceva cancer drug and become a bigger player in oncology.